Takeda Pharmaceutical Co. $TAK Position Increased by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC grew its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 376.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,882 shares of the company’s stock after buying an additional 112,092 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Takeda Pharmaceutical were worth $2,628,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of Takeda Pharmaceutical by 37.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 247,529 shares of the company’s stock valued at $3,624,000 after acquiring an additional 67,770 shares in the last quarter. Capital Research Global Investors grew its position in Takeda Pharmaceutical by 0.8% during the 3rd quarter. Capital Research Global Investors now owns 13,404,129 shares of the company’s stock worth $196,236,000 after purchasing an additional 108,556 shares in the last quarter. XY Capital Ltd purchased a new position in Takeda Pharmaceutical during the 3rd quarter worth approximately $2,928,000. China Universal Asset Management Co. Ltd. acquired a new stake in Takeda Pharmaceutical during the 4th quarter valued at $998,000. Finally, Sivia Capital Partners LLC acquired a new stake in Takeda Pharmaceutical during the 2nd quarter valued at $351,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $16.73 on Friday. The company has a market capitalization of $53.26 billion, a PE ratio of 42.91 and a beta of -0.07. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.60 and a current ratio of 1.09. The company’s 50 day moving average price is $16.09 and its 200 day moving average price is $16.86. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. Research analysts expect that Takeda Pharmaceutical Co. will post 0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TAK shares. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Sunday, June 28th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.